Antibe Therapeutics Inc(Pre-Merger) ATBPF

Healthcare

Antibe Therapeutics Inc. is a clinical-stage biotechnology company. The Company is leveraging its hydrogen sulfide (H2S) platform to develop therapies to target inflammation arising from a range of medical conditions. The Company’s pipeline includes assets that seek to overcome the gastrointestinal ulcers and bleeding associated with nonsteroidal anti-inflammatory drugs (NSAIDs). Its lead drug, otenaproxesul, is in clinical development as an alternative to opioids and NSAIDs for acute pain. Its second pipeline drug, ATB-352, is being developed for a specialized pain indication. The Company also focuses on inflammatory bowel disease (IBD). Otenaproxesul combines a moiety that releases hydrogen sulfide with naproxen, a non-steroidal, anti-inflammatory drug. ATB-352 is an H2S-releasing derivative of ketoprofen, a potent NSAID commonly prescribed for acute pain. Its IBD candidates are being designed to maintain the efficacy, safety, and pharmacokinetic properties of ATB-429.

GREY:ATBPF - Post by User

Antibe Therapeutics Inc(Pre-Merger) > Red candles

<< Previous

Bullboard Posts

Next >>

Comment by themagicboxon Aug 19, 2021 11:50am

105 Views

Post# 33730537

RE:RE:RE:RE:RE:Red candles

No one flexing here just calling out your BS. But I since you brought it up, turd, I actually got in on the last 2 bought deals and riding this thing on free warrants. So I'm riding this risk free. I will be sure to add on sub $1 and any future bought deals. So good luck mr. YOLO haha!!

But you keep trying to convicnce the forum you want this to succeed with your "25k shares" as you bash this stock based off of FUD. And the fact that your account was made on Aug 10 2021 is soooo transparent. haha

<< Previous

Bullboard Posts

Next >>

Investor’s corner: Solving chronic pain in dogs – A significant market opportunity